Category → Research Triangle
How many of you could say this about your laboratory group?
In the hall outside the champagne reception for Bob Lefkowitz’s lab on Wednesday at Duke University Medical Center, I had a chance to catch up with Marti Delahunty, PhD. Delahunty is a research scientist in a connecting building but worked in the Lefkowitz group from 1998 until 2006.
This brief chat brings to mind Carmen Drahl’s post about one’s laboratory being your second family.
PIs, trainees, technicians, and administrators: Tell me if you’d be able to say the same about the environment of your laboratory.
As discussed in my previous post, I took a personal day off from work yesterday to bask in the excitement of a university community celebrating a Nobel prize for one of its most beloved researchers, Dr. Robert “Bob” Lefkowitz, MD. He joined Duke in 1973 when, he says, “it was not the powerhouse it is today.”
Lefkowitz will share the prize with his former trainee, Brian Kobilka, MD, now at Stanford University.
I had the honor of joining his laboratory’s champagne celebration in the morning and the Duke University press conference in the early afternoon. (The full 47-minute press conference streamed live and is archived here at Duke.).
I live barely three miles from Duke and had no idea when or if I’d ever have the chance to be so close to such an event. The Lefkowitz prize is particularly meaningful to me as he is a biochemist physician-scientist who also considers himself a pharmacologist. So, I write this not so much as a journalist but rather — as Duke Research Communications Director Karl Leif Bates put it — a fan boy.
Defending the Chemistry Nobel for “biology” – again.
I’m near-certain that this is the first Nobel Prize in Chemistry given to two MDs. (10:31 am EDT: I was wrong, as per commenter Jonny below. Peter Agre, MD, and Roderick MacKinnon, MD, received the Nobel Prize in Chemistry 2003 for their work on aquaporins and other ion channels.)
Robert Lefkowitz, MD, of the Howard Hughes Medical Institute and Duke University Medical Center, and Brian Kobilka, MD, of Stanford University School of Medicine, will share the Nobel Prize in Chemistry 2012. The award recognizes a lifetime of work, certainly for Lefkowitz, in elucidating the action of the central chemical signal transducers of the human body.
This is a chemistry prize, albeit a biological chemistry prize.
The prize is being given for discovering how the body’s most important chemicals communicate their own chemical signals from outside the cell to inside. Without G-protein-coupled receptors, or GPCRs, our hearts would not beat, our lungs would not expand and contract, and our brains would be unable to regulate much of everything that runs in our bodies.
Moreover, the ubiquity of GPCRs have over history breathed tremendous life and stimulated innovation in chemistry to synthesize tools to modulate these receptors and thereby relieve human suffering. Chemists should revel in this prize – without G-protein coupled receptors, many chemists would not have been employed for the last few decades.
But I do agree that a case could be made for this prize to be given in Physiology or Medicine, particularly since GPCRs are central to physiology, “from plants to man.”
Feel free to vent your spleen in the comments below.
But do note that Derek Lowe, medicinal chemist and grand master of the chemblogosphere, has already decreed, “[M]y fellow chemists, cheer the hell up already.”
Disclosure: I hold an Adjunct Associate Professor appointment in the Duke University School of Medicine, Department of Medicine.
Designer drugs in the news
This is tiring enough for a science writer. I cannot imagine being in law enforcement.
The pace at which psychoactive designer drugs are appearing on the street is about as challenging for me as keeping up with dietary supplement companies that adulterate their products with actual prescription drugs (an area I’ve been covering since 2007 but a practice that goes back decades.)
This week’s designer drug hullabaloo comes to us courtesy of last week’s frightful murder-suicide by Sons of Anarchy actor, the late Johnny Lewis. ABC News is reporting today that Lewis was reportedly taking “Smiles,” a street name for 2C-I, the phenethylamine hallucinogen first synthesized by Alexander Shulgin.
2C-I is more properly known as 2,5-dimethoxy-4-iodophenethylamine. This structural analog of mescaline (3,4,5-trimethoxyphenylethylamine) was among a litany of designer drugs that was criminalized in the US back in July with the Synthetic Drug Abuse Prevention Act of 2012 (Cheryl Hogue had a nice discussion of the Act, including some quotes from yours truly, in the 27 August 2012 issue of C&EN.).
Continue reading →
In this quiet moment on a rainy Saturday evening in North Carolina Piedmont, I lie here in awe of the breadth of creative talent and boundless enthusiasm that this place attracts.
Tonight at 5:00 pm Eastern time, a couple hundred folks or so learned that they had not scored a slot in the lottery for the remaining spaces at ScienceOnline2013. I won’t be there this year either but I can certainly understand the disappointment. This simple idea of Bora Zivkovic along with Let’s-Get-Together-and-See-Where-This-Goes Guy, Anton Zuiker, has grown from a small gathering of likeminded online science enthusiasts to become the South-By-Southwest of science meetings, now under the exceptional leadership of Karyn Traphagen.
I encourage everyone to stay on or sign up for the waitlist. Lots of plans change between now and late January so registration slots will most certainly open up.
But in the meantime, you might consider another possibility that just happens to be available this year very near to the same GPS coordinates: ScienceWriters2012, the annual conference of the Council for the Advancement of Science Writing and the National Association of Science Writers.
Scheduled for October 26-30, 2012, ScienceWriters2012 will be headquartered at the very same hotel with a program crafted by a broad group of science communicators that include a subset of ScienceOnline folks. (For the record, we’re called Science Communicators of North Carolina, or SCONC.).
Here, look at the schedule yourself.
Catching up on my reading this Sunday morning, I’m beaming with pride on the collective accomplishments and coverage of some old friends and colleagues.
Kerstin Nordstrom, a AAAS Mass Media Fellow with the Raleigh News & Observer, had a nice story on 3 September about the work of Dr. Peter Stout at RTI International. You old-timers will know this non-profit entity as Research Triangle Institute, home to the discoveries of Taxol and camptothecin by Wall and Wani and colleagues.
Kerstin, or Dr. Nordstrom I should say as she holds a PhD in physics, interviews RTI’s Dr. Peter Stout on the institute’s forensic analytical chemistry capabilities with regard to the “designer drug” industry. Yes, here we go again with my long-running commentary on the “synthetic marijuana,” “herbal incense,” “plant food,” and “bath salts” products that have recently taken a direct hit from “Operation Log Jam,” a coordinated, federal operation to shut down the industry.
I need your help at the day job to show off chemistry to the masses.
Since joining our state museum in January, I’ve been a bit disappointed in general at how the world of chemistry is underpromoted across natural science museums. Even with all the hubbub over the Mars Curiosity rover and research lab, few folks know that the rover hosts a remarkable diversity of analytical chemistry instrumentation.
Saturday, October 13th is Chemistry Day at the NC Museum of Natural Sciences in Raleigh, just before National Chemistry Week. My colleagues tell me that it is one of the smaller of our “Days” and “Fests.” Well, I want to change that and, yes, I’m using this blog as a bully pulpit to do so. (I hope that’s okay, my benevolent overlords.)
With all the discord in Washington these days, it’s rare to see several US governmental organizations working together to address a significant public health problem.
This week, the US Drug Enforcement Agency (DEA) mobilized Operation Log Jam, an unusual and highly-coordinated action with six other federal agencies aimed to shut down the synthetic designer drug industry in 109 US cities. The products targeted were of two broad classes: 1) synthetic marijuana “incense” products comprised of naphthoylindole cannabimimetic compounds first synthesized by John W. Huffman’s lab at Clemson in the mid-1990s, and 2) “bath salts” or “plant food” products containing the stimulant/empathogen mephedrone (4-methylmethcathinone) or the stimulant MDPV (3,4-methylenedioxypyrovalerone).
This compilation of posts on synthetic marijuana and, to a lesser extent, “bath salts” serves as a good primer on the subject.